IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
IN8bio Presents Updated Clinical Data From INB-200 And INB-400 Programs In Newly Diagnosed GBM, In Oral Session At 2026 SNO Annual Meeting
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights
IN8bio to Present at Sidoti Small-Cap Virtual Conference
IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
IN8bio Q2 EPS $(0.25) Beats $(0.37) Estimate
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
IN8bio Announces Publication Of Peer-Reviewed Clinical Data From Phase 1 Trial Of INB-200 In The Journal Of Clinical Oncology
IN8bio (INAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
IN8bio Publishes Nature Communications Review Highlighting Engineered γδ T Cell Cancer Therapies And Combination Treatment Advances
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma
IN8bio Presents New Translational Data Of Its DeltEx DRI Platform At ISCT 2026 Annual Meeting And ASGCT 2026 Annual Meeting
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.